4.5 hours (Benchtop Protocol) or 2.5 hours (Shaker Protocol)
Sample Type & Volume Required Per Well
Serum (100 uL), EDTA Plasma (100 uL)
Natural and recombinant human Epo.
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference observed with other substances.
The Quantikine® Human Epo ELISA uses a monoclonal antibody and polyclonal antibody conjugate in a sandwich ELISA format. The assay is designed to measure Epo levels in serum or EDTA plasma in less than 4.5 hours, or less than 2.5 hours using the shaker protocol.
Intra-Assay Precision (Precision within an assay) Four samples of known concentration were tested thirty times to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Four samples of known concentration were tested in thirty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using three lots of components.
Serum, EDTA Plasma
The recovery of human Epo spiked to levels throughout the range of the assay was evaluated.
Average % Recovery
EDTA Plasma (Benchtop Protocol) (n=10)
EDTA Plasma (Shaker Protocol) (n=10)
Serum (Benchtop Protocol) (n=10)
Serum (Shaker Protocol) (n=10)
Five matched serum and plasma specimens containing elevated Epo concentrations were diluted with Specimen Diluent and assayed using the Quantikine Human Epo ELISA. Diluted specimens demonstrated very good linearity when compared to neat concentrations of Epo.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Erythropoietin (Epo) is a 30-kDa, heavily glycosylated protein produced primarily by the kidney. It is the principal factor that regulates erythropoiesis. The production of Epo by kidney cells is increased in response to hypoxia or anemia. The cDNAs for Epo have been cloned from many species. The mature proteins from the various species are highly conserved, exhibiting greater than 80% sequence identity at the amino acid level.
The biological effects of Epo are mediated by the Erythropoietin receptor (Epo R). At the protein sequence level, the human Epo R is approximately 83% identical to the mouse protein. As a result of alternative splicing of the Epo R gene, cDNA clones encoding truncated soluble forms of Epo R have been found. Recombinant soluble Epo R binds Epo with high affinity and is a potent Epo antagonist.